GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INVO Fertility Inc (NAS:NAYA) » Definitions » Gross Margin %

NAYA (INVO Fertility) Gross Margin % : 31.05% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Fertility Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. INVO Fertility's Gross Profit for the three months ended in Sep. 2024 was $0.45 Mil. INVO Fertility's Revenue for the three months ended in Sep. 2024 was $1.43 Mil. Therefore, INVO Fertility's Gross Margin % for the quarter that ended in Sep. 2024 was 31.05%.


The historical rank and industry rank for INVO Fertility's Gross Margin % or its related term are showing as below:

NAYA' s Gross Margin % Range Over the Past 10 Years
Min: -3.53   Med: 76.08   Max: 96.51
Current: 42.41


During the past 13 years, the highest Gross Margin % of INVO Fertility was 96.51%. The lowest was -3.53%. And the median was 76.08%.

NAYA's Gross Margin % is ranked worse than
66.76% of 743 companies
in the Biotechnology industry
Industry Median: 59.72 vs NAYA: 42.41

INVO Fertility had a gross margin of 31.05% for the quarter that ended in Sep. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for INVO Fertility was 0.00% per year.


INVO Fertility Gross Margin % Historical Data

The historical data trend for INVO Fertility's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Fertility Gross Margin % Chart

INVO Fertility Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.61 91.51 96.51 -3.53 35.95

INVO Fertility Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.41 35.82 46.07 53.08 31.05

Competitive Comparison of INVO Fertility's Gross Margin %

For the Biotechnology subindustry, INVO Fertility's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Fertility's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INVO Fertility's Gross Margin % distribution charts can be found below:

* The bar in red indicates where INVO Fertility's Gross Margin % falls into.


;
;

INVO Fertility Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

INVO Fertility's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1.1 / 3.021
=(Revenue - Cost of Goods Sold) / Revenue
=(3.021 - 1.935) / 3.021
=35.95 %

INVO Fertility's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0.4 / 1.433
=(Revenue - Cost of Goods Sold) / Revenue
=(1.433 - 0.988) / 1.433
=31.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


INVO Fertility  (NAS:NAYA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

INVO Fertility had a gross margin of 31.05% for the quarter that ended in Sep. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


INVO Fertility Gross Margin % Related Terms

Thank you for viewing the detailed overview of INVO Fertility's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Fertility Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
NAYA Biosciences Inc is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health. Its portfolio of assets currently includes NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) with a mode of action targeting non-responders to the current immunotherapy standard of care.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880